The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11115 malaria professionals are enjoying the free benefits of MalariaWorld today

p. vivax

Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice

November 25, 2021 - 13:04 -- Open Access
Arévalo-Herrera M, Miura K, Solano E, Sebastián Ramírez J, Long CA, Corradin G, Herrera S
Vaccine. 2021 Nov 18:S0264-410X(21)01481-X

Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malaria-endemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared.

NOT Open Access | Letter Regarding Kamau et al: 2021 Safety and Tolerability of Mosquito-Bite Induced Controlled Human Infection with P. vivax in Malaria-Naive Study Participants - Clinical Profile and Utility of Molecular Diagnostic Methods

October 16, 2021 - 11:56 -- NOT Open Access
Odedra A, Woodford J, Chalon S, Barber BE, McCarthy JS
J Infect Dis. 2021 Oct 5:jiab502

No abstract available

Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil

August 17, 2021 - 15:52 -- Open Access
Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, Soares Moura A, Advani N, Kahn M, Pal S, Gerth-Guyette E, Bansil P, Domingo GJ, Pereira D, Lacerda MV
PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009649

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzyme deficiency, prevalent in many malaria-endemic countries. G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment of P. vivax malaria.

Safety and Tolerability of Mosquito-Bite Induced Controlled Human Infection with P. vivax in Malaria-Naive Study Participants - Clinical Profile and Utility of Molecular Diagnostic Methods

June 30, 2021 - 09:34 -- Open Access
Kamau E, Bennett JW, Yadava A
J Infect Dis. 2021 Jun 23:jiab332

Plasmodium vivax controlled-human-malaria-infection (PvCHMI) is an important tool for the evaluation of drugs, vaccines and pathologies associated with this parasite. However, there is little data on its safety due to the limited number of PvCHMIs performed to-date.

NOT Open Access | Progress towards the development of a P. vivax vaccine

January 27, 2021 - 11:18 -- NOT Open Access
De SL, Ntumngia FB, Nicholas J, Adams JH
Expert Rev Vaccines. 2021 Jan 22

Plasmodium vivax causes significant public health problems in endemic regions. A vaccine to prevent disease is critical, considering the rapid spread of drug-resistant parasite strains, and the development of hypnozoites in the liver with potential for relapse. A minimally effective vaccine should prevent disease and transmission while an ideal vaccine provides sterile immunity. Areas covered: Despite decades of research, the complex life cycle, technical challenges and a lack of funding have hampered progress of P. vivax vaccine development.

Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study

January 6, 2021 - 13:13 -- Open Access
Nguyen TT, Nguyen XX, Gryseels C, et al.
Pathogens. 2020 Dec 31;10(1):E26

Malaria elimination in the Greater Mekong Sub-Region is challenged by a rising proportion of malaria attributable to P. vivax. Primaquine (PQ) is effective in eliminating the parasite's dormant liver stages and can prevent relapsing infections, but it induces severe haemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, highlighting the importance of testing enzyme activity prior to treatment.

NOT Open Access | Computational chemogenomics drug repositioning strategy enables the discovery of Epirubicin as a new repurposed hit for P. falciparum and P. vivax

June 30, 2020 - 14:57 -- NOT Open Access
Ferreira LT, Rodrigues J, Costa FTM, et al.
Antimicrob Agents Chemother. 2020 Jun 29:AAC.02041-19

Widespread resistance against antimalarial drugs thwarts current efforts for controlling the disease and urges the discovery of new effective treatments. Drug repositioning is increasingly becoming an attractive strategy since it can reduce costs, risks and time-to-market. Herein we have used this strategy to identify novel antimalarial hits. We performed a comparative in silico chemogenomics approach to select Plasmodium falciparum and P. vivax proteins as potential drug targets and analyzed these using a computer-assisted drug repositioning pipeline to identify approved drugs with potential antimalarial activity. Among seven drugs identified as promising antimalarial candidates, the anthracycline epirubicin was selected for further experimental validation.

Comprehensive proteomics investigation of P. vivax-infected human plasma and parasite isolates

March 9, 2020 - 14:20 -- Open Access
Venkatesh A, Aggarwal S, Kumar S, Rajyaguru S, Kumar V, Bankar S, Shastri J, Patankar S, Srivastava S
BMC Infect Dis. 2020 Mar 2;20(1):188

In recent times, Plasmodium vivax (P. vivax) has become a serious threat to public health due to its ability to cause severe infection with fatal outcomes. Its unique biology makes it resilient to control measures that are otherwise effective against P. falciparum. A deeper understanding of P. vivax biology and pathogenesis is, therefore, essential for developing the right control strategies. 

Humoral immunity prevents clinical malaria during Plasmodium relapses without eliminating gametocytes

October 1, 2019 - 14:29 -- Open Access
Chester J. Joyner, Cristiana F. A. Brito, Mary R. Galinski, et al.
PLoS Pathog 15(9): e1007974

Plasmodium relapses are attributed to the activation of dormant liver-stage parasites and are responsible for a significant number of recurring malaria blood-stage infections.

Medical Condition: 

Phosphoethanolamine-N-methyltransferase is a potential biomarker for the diagnosis of P. knowlesi and P. falciparum malaria

March 20, 2018 - 14:28 -- Open Access
Robert G. E. Krause, J. P. Dean Goldring
PLoS ONE 13(3): e0193833

PMT, like the pan-specific LDH biomarker used in RDT tests, is both soluble, present at comparable concentrations in the parasite and constitutes a promising antimalarial drug target.

Medical Condition: 
Medical Treatment: 


Subscribe to RSS - p. vivax